Allogene Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
All right. Good afternoon from the 40th Annual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm a senior large cap biotech analyst here. And it's my pleasure to introduce Allogene Therapeutics and CEO, David Chang. (Operator Instructions) So with that, David, thanks as always for joining us today, and let me turn things over to you for an update on Allogene.
Good afternoon, Corey, and thank you very much for having Allogene at this JPM Health Conference and Happy New Year to you all. I'm just going to move straight into the presentation. If you can just move to Slide 2. I just want to emphasize that we will be making forward-looking statements in this presentation, which are subject to risks, as stated in our SEC filing.
Moving to the next slide, in Slide 3. This slide really gives a snapshot of Allogene as we create the allogeneic South Turkey playbook. We
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |